Detected ·
Crystalys Therapeutics
$130M—
Crystalys Therapeutics announced the closing of a $130M Series B financing to support global clinical development and commercialization of dotinurad, a next-generation oral URAT1 inhibitor for the treatment of gout.
- Website
- crystalystx.com
- Amount
- $130 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-23 04:09:04 UTC
- Signal ID
- 91be0bd8-b1cb-40d5-a056-d57a66a45466
As the API returns it
{
"id": "91be0bd8-b1cb-40d5-a056-d57a66a45466",
"created_at": "2026-07-23T04:09:04.868399Z",
"company_name": "Crystalys Therapeutics",
"company_website_url": "crystalystx.com",
"company_linkedin_url": "https://www.linkedin.com/company/crystalys-therapeutics",
"event_type": "funding",
"funding_amount": 130000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Crystalys Therapeutics announced the closing of a $130M Series B financing to support global clinical development and commercialization of dotinurad, a next-generation oral URAT1 inhibitor for the treatment of gout.*"
}